RCUS vs IDYA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RCUS · Arcus Biosciences$15.62 ▼ 1.01%
IDYA · IDEAYA Biosciences$25.56 ▼ 2.33%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RCUS -32.6%
- IDYA -26.3%
Head to head
| Metric | RCUS | IDYA |
|---|---|---|
| Price | $15.62 | $25.56 |
| Change today | ▼ 1.01% | ▼ 2.33% |
| Market cap | $2.25B | $2.47B |
| Return, 3 months | -48.1% | -36.2% |
| Return, year to date | -34.5% | -26.1% |
| Return, 1 year | -29.2% | -24.8% |
| P/E (TTM) | – | – |
| P/B | 6.3 | 2.3 |
| P/E percentile vs own 5y | 46th | 83rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -65.4% | -95.1% |
| Net profit growth (YoY) | +5.2% | -205.5% |
| Gross margin | – | – |
| Operating margin | -475.0% | -1,267.3% |
| Net margin | -453.0% | -1,149.6% |
| Return on equity | -114.1% | -38.5% |
| Analyst target vs. price | +166.6% | +107.0% |
| Analyst buy share | 83% | 100% |
| RSI (14) | 29 | 25 |
| 30-day volatility | 83.2% | 52.8% |
| Max drawdown, 1 year | -50.5% | -39.8% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- IDYA is the largest of the group by market value.
- IDYA has returned the most over the past year.
- RCUS is growing revenue fastest.
- RCUS keeps the most profit per dollar of sales.
- IDYA has been the calmest stock over the last 30 days.